MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform that a routine eGMP inspection was conducted by USFDA at manufacturing facility of the Company in Verna Goa. There was no data integrity observation. MARKSANS PHARMA LTD. - 524404 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company MARKSANS PHARMA LTD. 2 CIN NO. L24110MH1992PLC066364 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2023-24,02024-25, 2025-26 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2023-24. 2024-25, 2025-26 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Harshavardhan PanigrahiDesignation :-Company Secretary Name of the Chief Financial Officer :- Jitendra Sharma Designation : -Chief Financial Officer Date: 15/04/2024 MARKSANS PHARMA LTD. - 524404 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyMARKSANS PHARMA LTD. 2CIN NO.L24110MH1992PLC066364 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harshavardhan Panigrahi Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: JItendra Sharma Designation: Chief Financial Officer EmailId: [email protected] Date: 15/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Kindly find enclosed herewith under regulation 74(5) of DP regulations for quarter ended March 31, 2024 received form big share Services Private Limited MARKSANS PHARMA LTD. - 524404 - Compliance Certificate Under Regulation 40(9) & 40(10)
Pursuant to regulation 40(9) & 40(10) of SEBI LODR, kindly find enclosed compliance certificate issued by Sanjay Dholakia & Associates-PCS, for FY2024 MARKSANS PHARMA LTD. - 524404 - Compliance Certificate Under Regulation 7(3) Of SEBI LODR For The Period Ended March 31, 2024
We confirm that all activities in relation to share transfer facilities of the Company during the FY2024 were maintained by RTA - Big share services private limited MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received intimation from our RTA regarding issuance of duplicate share certificate the details of which have been attached MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received 1 request form a shareholder for issuing of duplicate share certificate on April 02, 2024 the details of which have been attached MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
The trading window for dealing in shares of Marksans Pharma Limited for the Designated persons will remain closed form Monday April 01, 2024 till 48 hours after the declaration of Audited financial results for the quarter and financial year ended march 31, 2024 MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Kindly find enclosed the transcript of investors/analysts meet for Q3FY24 financial performance